MedTrace Logo

Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes

NCT00574834 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2019-09-12

Study results available
· View outcomes & findings →

Summary

The study will be focused on determining the integrated in-vivo mechanisms responsible for Ramipril's effects on delaying type 2 diabetes and restoring normal (blood sugar levels) glycemia in patients with impaired glucose tolerance.

Hypothesis - Ramipril effects will delay the onset of type 2 diabetes and restore normal glycemia in patients with impaired glucose tolerance.

Conditions

  • Metabolic Syndrome

Interventions

DRUG

Ramipril

Ramipril 20 mg once daily for 6 months

DRUG

HCTZ-hydrochlorothiazide

HCTZ 25 mg once daily for 6 months

DRUG

Ramipril+HCTZ

Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months

Sponsors & Collaborators

  • King Pharmaceuticals is now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Stephen N. Davis, MD, FRCP · University of Maryland, Baltimore

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00574834 on ClinicalTrials.gov